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Th  e goal of personalised medicine is a top priority for 
current clinical research and in the UK this has been 
recognised by the development of a Stratiﬁ  ed Medicines 
Initiative, which is being led by the Medical Research 
Council. Although oncology is unique among disciplines 
in its personalisation, being markedly inﬂ  uenced  by 
somatic mutations, it is expected to be in the vanguard of 
developments under this initiative. Given that breast 
cancer is the most advanced malignancy in terms of 
biomarkers and molecular signatures used for stratiﬁ  ca-
tion of treatment, it is a key disease for inclusion in this 
initiative. Th  e communications in this section of the 
meet  ing report are therefore particularly timely. Th  e 
papers are separated to deal with two main issues. Firstly, 
what are the opportunities, constraints and requirements 
for the establishment of predictive and prognostic factors 
that have clinical utility, and are there new ways in which 
we can integrate these into a pathological understanding 
of the disease? Secondly, does molecular proﬁ  ling 
currently oﬀ  er any more than tumour histology or basic 
immunochemistry for clinical application?
Dr Hayes considers the manner in which we should 
develop biomarkers and the emphasis that should be 
placed upon them to elicit maximum value. Th  e  overall 
theme is that a bad biomarker is as bad as a bad drug. To 
this a subtext can be added: a good biomarker can at 
times make a poor drug good (at least in a subset of 
patients), and a bad biomarker can also make a good drug 
bad by guiding treatment inaccurately. Th  e  most 
important issue is that we should be placing the same 
resources and rigour behind marker development as we 
do the development of drugs: current expenditure and 
eﬀ   ort are badly out of proportion to the relative 
importance of biomarkers.
It has taken many years to create authoritative guide-
lines for the conduct of HER2 diagnostics, and even 
longer for those guiding steroid receptor analyses; 
however, the recent alliance of oncologists from 
American Society of Clinical Oncology and pathologists 
from the College of American Pathologists has created 
guidelines [1,2] that will hopefully improve the accuracy, 
precision and consistent interpretation of these tests, 
which have enormous importance for selecting appro-
priate therapy. While it will take some time for full 
guidelines to be developed for new markers, it is appro-
priate that those involved in the assessment of highly 
encouraging emergent markers should meet early and 
gather best evidence for harmonisation of approaches to 
analysis, scoring and reporting, such that comparability 
between their assessments can be ensured and a rapid 
assessment of the markers’ true importance be established.
Th  e level of evidence for bringing a marker into 
recommended clinical usage is rightly conservative given 
that inappropriate application would lead to incorrect 
treatment of patients. Early acquisition of such evidence 
requires attention to good study design and validity of 
methodology. In the past it has been felt necessary to 
have a prospective clinical study that demonstrates un-
equivocally the value of a marker in stratifying patient 
therapy; however, Simon and colleagues [3] recently 
concluded that level one evidence may be obtained from 
two independent retrospective/prospective analyses that 
are suﬃ     ciently powered and separately conﬁ  rm  the 
biomarker-led separation of groups of diﬀ  ering outcome.
Unfortunately, at the present time, the value of tumour 
biomarkers appears to be underestimated and certainly 
under-funded: the diagnostics market is massively out-
weighed by the therapeutics market in oncology. None-
theless, recent initiatives to identify the costs that may be 
saved by appropriate application of a new diag  nostic are 
beginning to allow the application of markers that look 
expensive compared to those in the past, but in fact 
reﬂ   ect the investment required for rigorous quality 
control and high reproducibility.
Dr Mills considers the bias and artefacts that may occur 
both in the preclinical laboratory and in molecular 
pathology laboratories assessing clinical specimens. A 
number of factors inﬂ   uence this: the requirement for 
separate training and test sets of samples has been well 
established in clinical studies but is less well applied in 
molecular biology. In the clinical laboratory it is becom-
ing clear that while some markers are relatively resistant 
to degradation in the time that ﬁ   xation occurs by  © 2010 BioMed Central Ltd
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© 2010 BioMed Central Ltdformalin or other preservatives, certain markers are 
much more labile. Evidence for this has recently been 
gathered from an assessment of pERK and pAKT in core-
cut biopsies and pieces of surgical excisions taken at the 
time of operation or subsequent to routine ﬁ  xation [4]. 
Striking and consistently lower values for each of these 
markers were found in excision biopsies, and it seems 
almost certain that this is due to the slow penetrance of 
formalin into tissues (approximately 1 mm per hour) and, 
therefore, the opportunity for loss of marker integrity. 
Th  e actual preservation in excision biopsies is likely to 
reﬂ  ect the protocols that are used for ﬁ  xing tumours in 
diﬀ   erent establishments. Th   us, substantial analytical 
noise may be introduced into assessments of these and 
similarly aﬀ  ected markers in excision biopsies and will 
aﬀ  ect studies by tissue microarray analysis, which are 
being increasingly used for clinical research. Th  e 
degradation that may have occurred to an unknown 
degree through the excision biopsies must, therefore, be 
recognised as potentially leading to false negative results. 
It should also be noted that false positive results might be 
apparent if, for example, core cuts were compared with 
sections of an excision biopsy in a short term ‘window of 
opportunity’ study: the apparent reduction in pAKT and 
pERK could, in these circumstances, be read as evidence 
of therapeutic eﬃ   cacy.
Heterogeneity of biomarkers is becoming increasingly 
recognised to occur at numerous levels, including diﬀ  er-
ent mutations across a single tumour as well as between 
lesions in a single patient. Th   is provides challenges to the 
concept of personalised medicine where the biology of 
diﬀ  erent lesions or within a lesion may be highly variable. 
Overall, it is helpful to regard all of the measures that we 
make in molecular pathology or immunohistochemistry 
to be artefactual in some manner: the way in which that 
artefact is measured should be considered in the context 
of its ﬁ  tness for the purpose to which it will be applied.
Alongside these complications to the consistent 
measurement of biomarkers, Dr Faratian considers the 
new science of systems biology and the potential to 
extend this to systems pathology. In systems biology, 
extreme control of experimental design and output is 
needed to understand the impact of perturbations on the 
system and the regulatory systems that react to such 
change. It seems unreasonable to consider that this 
degree of control can be exerted within a clinical experi-
mental situation. In addition, the requisite validity for an 
assessment of the concentration or activity of a given 
biological entity needed for systems biology/pathology 
requires precision and analytical abilities that go well 
beyond those required for standard biomarker analyses. 
Time will tell whether consideration of biological systems 
using biomarker measurements in biopsy tissues is a 
realistic possibility.
Th   e other authors in this session deal with the question 
of whether these new markers oﬀ  er more to the clinician 
than histopathology or basic biomarkers. It has been 
heartening over recent years to ﬁ  nd that certain mole-
cular proﬁ  les, most notably the Oncotype Dx Recurrence 
Score, have shown suﬃ     cient clinical utility that their 
relatively expensive nature does not prevent them from 
being widely applied in health systems with suﬃ   cient 
funding. Taking the Recurrence Score as the most 
relevant example, it is notable that the developers of this 
had a strategy that enhanced the likelihood of success. 
Th  is included the identiﬁ  cation of a clinical question of 
current and continuing clinical importance, that is, the 
identiﬁ   cation of those oestrogen-receptor-positive 
patients on endocrine therapy who were node negative 
and whose risk of recurrence was so low as to safely 
exclude them from the application of cytotoxic 
chemotherapy. In addition, technology was developed 
that not only was applicable to the most widely available 
pathological material (formalin-ﬁ  xed, paraﬃ   n-embedded 
blocks) but also was shown to be valid in tissues derived, 
in some cases, from samples taken over three decades 
ago. One thing that has become apparent is that the 
molecular information that drives the Recurrence Score 
is of similar magnitude to, but also diﬀ  ers almost entirely 
from, the information that is gathered from clinico-
pathological parameters, such as nodal status, tumour 
size and histo-pathological grade. Given the indepen-
dence of these two measures, the opportunity to integrate 
these into a tool that is more powerful than either alone 
is attractive and has been now addressed by a colla  bora-
tion of the ATAC (Arimidex, Tamoxifen, Alone or in 
Combination) and the NSABP (National Surgical 
Adjuvant Breast and Bowel Project) trialists [5].
Th   e value of the Recurrence Score in reducing the cost 
of cytotoxic chemotherapy (let alone the prevention of 
toxicity in patients not needing the treatment) has been 
well-recorded, but even this to date has not been suﬃ   cient 
to have the test recommended by health authori  ties in the 
UK or in many other parts of the western world. Th  e  ability 
for standard immuno  histo  chemical measurement of the 
oestrogen receptor, proges  terone receptor, Ki67 and HER2 
to provide at least as much prognostic information as the 
Recurrence Score has recently been demonstrated [6]. 
While this may eventually be shown to be a viable 
alternative, for this to be the case the standardisation that 
is required for routine implementation will need to be 
forthcoming. Th   us, at the present time, molecular patho-
logy probably does oﬀ  er rather more than tumour morph-
o  logy and basic immunohistochemistry, but the degree to 
which this is the case may frequently be overstated.
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